Tests deucravacitinib in children with juvenile psoriatic arthritis
Tests deucravacitinib against placebo in children aged 5 to 17 with juvenile psoriatic arthritis.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Key facts
- Where
- Belo Horizonte, Cuiabá, Curitiba, Fortaleza, Porto Alegre, Recife, Rio de Janeiro, São Paulo, Vila Clementino, and Xangri-lá, BrazilSee the 13 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 5 and 17 years old?
Source: NCT06869551, who can take part
Where in Brazil
- Santa Casa de Misericordia de Belo HorizonteBelo Horizonte, BrazilTaking people
- CuiabáCuiabá, BrazilNo longer taking part
- Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à InfânciaCuritiba, BrazilTaking people
- CuritibaCuritiba, BrazilNo longer taking part
- Centro de Oncologia Leonardo Da Vinci - ATO TerapiasFortaleza, BrazilTaking people
- LMK Servicos Medicos S SPorto Alegre, BrazilTaking people
- Porto AlegrePorto Alegre, BrazilNo longer taking part
- Hospital das Clínicas - UFPERecife, BrazilTaking people
- Rio de JaneiroRio de Janeiro, BrazilNot yet recruiting
- Santa Casa Instituto de PesquisaSão Paulo, BrazilTaking people
- São PauloSão Paulo, BrazilNo longer taking part
- PSEG- Pesquisa ClínicaVila Clementino, BrazilTaking people
- Hospital Lifeplus Litoral NorteXangri-lá, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06869551EU 2024-517262-41-00
- Record updated
- 6 October 2026
- Original description
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.Read full original descriptionShow less
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Inclusion: Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA); Participants must have at least three joints that are affected by arthritis; Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.
Exclusion: Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months; Participants must not have been diagnosed with JPsA before 5 years of age; Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,; Other protocol-defined Inclusion/Exclusion criteria apply.